US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Quasi-New Stocks

676.94

-7.5444-1.10%

Number of Gainers:34

Number of Losers:111

Number of Flat:22

PE:- -

High:684.60

Open:684.60

Low:673.75

Close:684.65

Volume:18.56M

Turnover:479.72M

Market Cap:504.32B

Float Cap:365.32B

Loading ...

Waterdrop Inc. files Form 3 disclosing VP of Human Resources Xiaolei Sun’s 4.2 million Class A shares

New Wedding Traditions and Modern Trends: Rejecting Excessive Bride Prices, Promoting Civilized Marriage Customs

Assertio Therapeutics Banks on Robodon After Volatile Q4

Kaltura Balances Record Profits With Slower Growth

1stdibs.com General Counsel and CPO Melanie F Goins disposes of USD 550 common shares

Overview of Ninth Municipal Party Committee's Ninth Round Inspection Assignments

Oklo Misses Q4 Estimates, Announces Department Of Energy Approval For Isotope Facility

Kaltura (KLTR) Losses Narrow Again In Q3 FY 2025 Challenging Bearish Profitability Concerns

Simply Wall St.

Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors

Dermata Therapeutics SVP Regulatory Affairs Maria E Bedoya-Toro Munera acquires USD 1,270 in common shares

US stocks open higher as Dow jumps while crypto equities struggle for direction

Nuvalent to present zidesamtinib data at AACR Annual Meeting 2026

Alignment Healthcare President Dawn Christine Maroney Disposes of USD 524,427 in Common Shares

Karat Packaging names BDO as auditor and dismisses PwC

Oklo Gets a Regulatory Win as Losses Keeps Widening -- Update

Oklo Inc reports results for the quarter ended December 31 - Earnings Summary

Press Release: Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

TaskUs Amends Credit Agreement to Enhance Financial Flexibility

Frontier Group Adjusts Airbus Orders, Reduces Leased Fleet

Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4539/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4539","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","market":"US","secType":"PLATE","nameCN":"Quasi-New Stocks","latestPrice":677.1096,"timestamp":1773840766667,"preClose":684.654,"halted":0,"volume":18535230,"delay":0,"changeRate":-0.011019,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-7.544373,"latestTime":"03-18 09:32:46 EDT","open":684.60364,"high":684.60364,"low":673.75195,"amount":479719158.243708,"amplitude":0.01585,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1773864000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.514458,"peRate":191.00821,"turnoverRate":0.001317,"increases":34,"decrements":111,"flats":16,"marketCap":504324125626.5,"floatMarketCap":365322644227.75},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4539\",,,,,undefined,":{"symbol":"BK4539","high":684.60364,"amplitude":0.01585,"preClose":684.654,"low":673.75195,"pbRate":"5.514458","latestPrice":676.9377,"volume":18555226,"delay":0,"open":684.60364,"prevYearClose":881.5255,"prevWeekClose":667.2545,"prevMonthClose":663.4647,"prevQuarterClose":881.5255,"fiveDayClose":685.7833,"twentyDayClose":647.1938,"sixtyDayClose":907.4049,"secType":"PLATE","market":"US","turnoverRate":0.00132,"peRate":191.00821,"marketCap":504281163622.125,"floatMarketCap":365286147910.375,"timestamp":1773840768323,"nameCN":"Quasi-New Stocks"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4539\",,,,undefined,":{"bkCode":"BK4539","up":34,"down":111,"flat":22},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4539\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2620014407","title":"Waterdrop Inc. files Form 3 disclosing VP of Human Resources Xiaolei Sun’s 4.2 million Class A shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620014407","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620014407?lang=en_us&edition=fundamental","pubTime":"2026-03-18 09:27","pubTimestamp":1773797263,"startTime":"0","endTime":"0","summary":"Waterdrop reported an initial statement of beneficial ownership by Xiaolei Sun, a director and VP of Human Resources. Sun reported indirect beneficial ownership of 4.2 million Class A ordinary shares. Sun also reported direct beneficial ownership of 4.6 million Class A ordinary shares. Sun reported share options covering 800,000 Class A ordinary shares with an exercise price of USD 0.08 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Waterdrop Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL5P8XM1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WDH","BK4509","BK4539","BK4173"],"gpt_icon":0},{"id":"1136368625","title":"New Wedding Traditions and Modern Trends: Rejecting Excessive Bride Prices, Promoting Civilized Marriage Customs","url":"https://stock-news.laohu8.com/highlight/detail?id=1136368625","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136368625?lang=en_us&edition=fundamental","pubTime":"2026-03-18 09:01","pubTimestamp":1773795711,"startTime":"0","endTime":"0","summary":"New wedding traditions and modern trends are emerging, advocating for the rejection of excessive bride prices and the promotion of civilized marriage customs.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4023","LU0353189763.USD","LU1852331112.SGD","BK4613","LU2290526834.HKD","SINA","APPX","IE00BZ9MQY76.HKD","LU2063271972.USD","IE00B19Z9Z06.USD","LU0056508442.USD","IE00B894F039.SGD","BK4588","LU0353189680.USD","LU2250418816.HKD","IE00B19Z9P08.USD","APP","LU2360106780.USD","LU2360107168.USD","LU2087625088.SGD","LU0097036916.USD","LU1861220033.SGD","BK4608","BK4585","LU1861215975.USD"],"gpt_icon":0},{"id":"2620044234","title":"Assertio Therapeutics Banks on Robodon After Volatile Q4","url":"https://stock-news.laohu8.com/highlight/detail?id=2620044234","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620044234?lang=en_us&edition=fundamental","pubTime":"2026-03-18 08:08","pubTimestamp":1773792500,"startTime":"0","endTime":"0","summary":"Assertio Therapeutics (($ASRT)) has held its Q4 earnings call. Read on for the main highlights of the call. Assertio Therapeutics’ latest earnings ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/assertio-therapeutics-banks-on-robodon-after-volatile-q4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/assertio-therapeutics-banks-on-robodon-after-volatile-q4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4539","ASRT","BK4139","BK4007"],"gpt_icon":0},{"id":"2620042284","title":"Kaltura Balances Record Profits With Slower Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2620042284","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620042284?lang=en_us&edition=fundamental","pubTime":"2026-03-18 08:02","pubTimestamp":1773792167,"startTime":"0","endTime":"0","summary":"Kaltura, Inc. (($KLTR)) has held its Q4 earnings call. Read on for the main highlights of the call. Kaltura’s latest earnings call struck a cautiou...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kaltura-balances-record-profits-with-slower-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kaltura-balances-record-profits-with-slower-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4023","BK4539","KLTR"],"gpt_icon":0},{"id":"2620010664","title":"1stdibs.com General Counsel and CPO Melanie F Goins disposes of USD 550 common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620010664","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620010664?lang=en_us&edition=fundamental","pubTime":"2026-03-18 07:57","pubTimestamp":1773791848,"startTime":"0","endTime":"0","summary":"Melanie Goins, General Counsel and CPO of 1stdibs.com, reported a disposal of 7 common shares on March 13, 2026. Goins reported a disposal of 69 common shares on March 16, 2026. Goins reported a disposal of 24 common shares on March 17, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 1stdibs.com Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL4tqXKn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"1stdibs.com General Counsel and CPO Melanie F Goins disposes of USD 550 common shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4220","BK4122","DIBS","BK4539"],"gpt_icon":0},{"id":"1130556187","title":"Overview of Ninth Municipal Party Committee's Ninth Round Inspection Assignments","url":"https://stock-news.laohu8.com/highlight/detail?id=1130556187","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130556187?lang=en_us&edition=fundamental","pubTime":"2026-03-18 07:41","pubTimestamp":1773790918,"startTime":"0","endTime":"0","summary":"Details of the inspection assignments for the ninth round conducted by the Ninth Municipal Party Committee have been disclosed. For comprehensive information and detailed analysis, please refer to the Sina Finance app.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z9Z06.USD","APPX","LU1852331112.SGD","LU2063271972.USD","LU1861220033.SGD","BK4613","LU2360107168.USD","BK4539","BK4023","LU2250418816.HKD","LU2360106780.USD","BK4588","LU0097036916.USD","LU0353189680.USD","IE00B894F039.SGD","IE00B19Z9P08.USD","LU0056508442.USD","BK4608","LU0353189763.USD","BK4585","IE00BZ9MQY76.HKD","LU1861215975.USD","LU2087625088.SGD","LU2290526834.HKD"],"gpt_icon":0},{"id":"2620403712","title":"Oklo Misses Q4 Estimates, Announces Department Of Energy Approval For Isotope Facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2620403712","media":"Benzinga","labels":["policyRegulatory","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620403712?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:57","pubTimestamp":1773788259,"startTime":"0","endTime":"0","summary":"Oklo Inc (NYSE:OKLO) reports financial results for the fourth quarter of 2025 after the market close on Tuesday.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/03/51312957/oklo-misses-q4-estimates-announces-department-of-energy-approval-for-isotope-facility","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Oklo Misses Q4 Estimates, Announces Department Of Energy Approval For Isotope Facility","news_tag":"policyRegulatory,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKLO","BK4081","OKLS","OKLL","BK4606","BK4539"],"gpt_icon":0},{"id":"2620876401","title":"Kaltura (KLTR) Losses Narrow Again In Q3 FY 2025 Challenging Bearish Profitability Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2620876401","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620876401?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:24","pubTimestamp":1773786262,"startTime":"0","endTime":"0","summary":"Kaltura FY 2025 earnings snapshot\nKaltura (KLTR) has just posted its FY 2025 third quarter numbers, reporting revenue of US$43.9 million and a basic EPS loss of US$0.02, alongside net income excluding extra items of a US$2.6 million loss. The company’s recent quarterly revenue has moved from US$45.6 million in Q4 2024 to US$44.5 million in Q2 2025 and US$43.9 million in Q3 2025. Over the same period, basic EPS has ranged between a loss of US$0.07 and a loss of US$0.02. The latest figures...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/software/nasdaq-kltr/kaltura/news/kaltura-kltr-losses-narrow-again-in-q3-fy-2025-challenging-b","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/software/nasdaq-kltr/kaltura/news/kaltura-kltr-losses-narrow-again-in-q3-fy-2025-challenging-b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["KLTR","BK4023","BK4539"],"gpt_icon":0},{"id":"2620401185","title":"Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2620401185","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620401185?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:54","pubTimestamp":1773784440,"startTime":"0","endTime":"0","summary":"ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (A","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257773/0/en/Acrivon-Therapeutics-to-Present-Pre-Clinical-AP3-Data-at-the-2026-AACR-Annual-Meeting-Revealing-Strong-Synergy-of-ACR-368-with-ADC-Topo-1-Inhibitor-Payloads-and-of-both-ACR-368-and.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","BK4539","LENZ","BK4080","ADC","BK4139","ACR","BK4110","BK4007"],"gpt_icon":0},{"id":"2620040681","title":"Dermata Therapeutics SVP Regulatory Affairs Maria E Bedoya-Toro Munera acquires USD 1,270 in common shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620040681","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620040681?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:44","pubTimestamp":1773783897,"startTime":"0","endTime":"0","summary":"Maria Bedoya-Toro Munera, SVP of Regulatory Affairs at Dermata Therapeutics, reported the acquisition of 1,000 common shares at USD 1.27 per share. Following the transaction, she reported direct beneficial ownership of 1,012 common shares. She also reported indirect beneficial ownership of 34 common shares held through the Munera Family Trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dermata Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL9kNvFw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Dermata Therapeutics SVP Regulatory Affairs Maria E Bedoya-Toro Munera acquires USD 1,270 in common shares","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","DRMA","BK4539"],"gpt_icon":0},{"id":"2620440508","title":"US stocks open higher as Dow jumps while crypto equities struggle for direction","url":"https://stock-news.laohu8.com/highlight/detail?id=2620440508","media":"cryptonews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620440508?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:30","pubTimestamp":1773783000,"startTime":"0","endTime":"0","summary":"U.S. stocks opened higher on Tuesday, extending a riskon regime across the Dow, S&P 500 and Nasdaq even as cryptolinked names like Coinbase and MicroStrategy once again trade more like volatile Bitcoin proxies than companies being valued on their own fundamentals.Gate data cited by ChainCatcher show the Dow opening up 0.66%, the S&P 500 up 0.42% and the Nasdaq up 0.33%, extending a riskon regime where dips in U.S. equities remain shallow and quickly bought.Cryptolinked stocks like Coinbase and MicroStrategy continue to trade less on cash flows and business execution and more as leveraged wrappers on Bitcoin, with sharp pops on strong BTC and ETF inflow days often fading as spot volatility cools.U.S. stocks opened higher on Tuesday, with risk appetite still firmly intact even as traders digest a busy macro and corporate tape. According to Gate market data cited by ChainCatcher, the Dow Jones Industrial Average opened up 0.66%, the S&P 500 rose 0.42%, and the Nasdaq Composite gained 0.33","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"crypto_news_highlight","url":"https://crypto.news/us-stocks-open-higher-as-dow-jumps-while-crypto-equities-struggle-for-direction/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://crypto.news/us-stocks-open-higher-as-dow-jumps-while-crypto-equities-struggle-for-direction/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"crypto_news_highlight","symbols":["CONY","BK4596","ICOI","LU1861559042.SGD","LU2360107671.USD","BK4112","FIAT","COIG","CONX","BITO","BK4594","BK4588","BK1611","BK4535","LU1861220207.SGD","BK4595","COIN","LU1861217088.USD","BK4601","BK4600","BK4554","COIO","BK4585","BK4539","COIW","CONI","COII","COIA","COYY","BK4516","BK4551","83042","LU1861558580.USD"],"gpt_icon":1},{"id":"2620405964","title":"Nuvalent to present zidesamtinib data at AACR Annual Meeting 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620405964","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620405964?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:16","pubTimestamp":1773782186,"startTime":"0","endTime":"0","summary":"Nuvalent will present new clinical and preclinical data on zidesamtinib at the AACR Annual Meeting 2026, held April 17-22, 2026, in San Diego. On April 21, 2026 , Geoffrey Liu will present poster CT248, “Zidesamtinib in Patients with ROS1+ NSCLC Previously Treated with Repotrectinib or Taletrectinib” (). On April 21, 2026 , Anupong Tangpeerachaikul will present poster LB366, “Zidesamtinib Has Differentiated Preclinical Brain Penetrance and Intracranial Activity Compared to Other ROS1 Inhibitors” ().","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDLbrTkPD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","NUVL"],"gpt_icon":0},{"id":"2620059614","title":"Alignment Healthcare President Dawn Christine Maroney Disposes of USD 524,427 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620059614","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620059614?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:15","pubTimestamp":1773782129,"startTime":"0","endTime":"0","summary":"Dawn Christine Maroney, President of Alignment Healthcare, reported a disposal of 30,000 common shares. The shares were sold at a weighted-average price of USD 17.48 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alignment Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL1RRBLz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alignment Healthcare President Dawn Christine Maroney Disposes of USD 524,427 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALHC","BK4154","BK4539"],"gpt_icon":0},{"id":"2620405558","title":"Karat Packaging names BDO as auditor and dismisses PwC","url":"https://stock-news.laohu8.com/highlight/detail?id=2620405558","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620405558?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:06","pubTimestamp":1773781575,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Karat Packaging Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 17, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL6C2vF4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","KRT","BK4539"],"gpt_icon":0},{"id":"2620405372","title":"Oklo Gets a Regulatory Win as Losses Keeps Widening -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620405372","media":"Dow Jones","labels":["policyRegulatory","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620405372?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:04","pubTimestamp":1773781440,"startTime":"0","endTime":"0","summary":"Oklo received approval from the Energy Department to move ahead with building an isotope test reactor in Texas, as the company's fiscal-year loss widened.The approval allows Oklo's subsidiary Atomic Alchemy to advance to the next phase of developing its isotope facility. Atomic Alchemy is targeting criticality--where the reactor is self-sustaining--at its Texas facility by July 2026. The site is located near Lockhart in Caldwell County.The isotope plant will help the nuclear-energy company gather data it can apply to subsequent licensing submissions and deployments, Chief Executive Jacob DeWitte said.The facility is intended to lay the groundwork for future commercial plants that produce isotopes in the U.S. The plants are designed to support cancer diagnosis and treatment, advanced manufacturing, scientific and space research, and national security needs.The Energy Department's approval is part of its Reactor Pilot Program, which is designed to provide a framework for building and ope","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKLL","BK4539","OKLO","BK4606","OKLS","BK4081"],"gpt_icon":1},{"id":"2620822405","title":"Oklo Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2620822405","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620822405?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:01","pubTimestamp":1773781298,"startTime":"0","endTime":"0","summary":"Oklo Inc reports results for the quarter ended December 31 - Earnings SummaryOklo Inc OKLO.N reported a quarterly adjusted loss of 27 cents per share for the quarter ended December 31, lower than the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nL8N4052DB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OKLO","BK4606","OKLS","BK4539","BK4081","OKLL"],"gpt_icon":1},{"id":"2620861405","title":"Press Release: Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620861405","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620861405?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:01","pubTimestamp":1773781260,"startTime":"0","endTime":"0","summary":"Throughout the year, the Company reported significant positive preclinical findings for SIL204 across eight KRAS mutations and four cancer types, including first evidence of activity in gastric cancer, reinforcing broad therapeutic potential. During the fourth quarter, Silexion achieved key clinical readiness milestones including completing two-species toxicology studies, written Scientific Advice from Germany's BfArM, and submission of Phase 2/3 clinical trial application to the Ministry of Health in Israel for SIL204 in locally advanced pancreatic cancer. The Company remains on track to initiate Phase 2/3 clinical trial in the first half of 2026, with Israel regulatory feedback anticipated by the end of Q1 2026. Regulatory Advancement Toward Phase 2/3 Initiation: Silexion received written Scientific Advice from Germany's Federal Institute for Drugs and Medical Devices  regarding the design of its planned Phase 2/3 clinical trial. The Company subsequently submitted its Phase 2/3 clini","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLXN","BK4023","LENZ","BK4007","BK4539","BK4535","BK4503","API","BK4551"],"gpt_icon":0},{"id":"2620885405","title":"TaskUs Amends Credit Agreement to Enhance Financial Flexibility","url":"https://stock-news.laohu8.com/highlight/detail?id=2620885405","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620885405?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:58","pubTimestamp":1773781136,"startTime":"0","endTime":"0","summary":"TaskUs ( ($TASK) ) has shared an announcement. On March 11, 2026, TaskUs subsidiary TU BidCo, Inc. entered into a Second Amended and Restated Credi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/taskus-amends-credit-agreement-to-enhance-financial-flexibility?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/taskus-amends-credit-agreement-to-enhance-financial-flexibility?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4106","TASK","BK4226","BK4535","BK4539"],"gpt_icon":0},{"id":"2620079403","title":"Frontier Group Adjusts Airbus Orders, Reduces Leased Fleet","url":"https://stock-news.laohu8.com/highlight/detail?id=2620079403","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620079403?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:55","pubTimestamp":1773780920,"startTime":"0","endTime":"0","summary":"Frontier Group Holdings ( ($ULCC) ) has issued an announcement. On March 11, 2026, Frontier Airlines amended its long-standing Airbus A320 family p...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/frontier-group-adjusts-airbus-orders-reduces-leased-fleet?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/frontier-group-adjusts-airbus-orders-reduces-leased-fleet?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","ULCC","BK4500","BK4008"],"gpt_icon":0},{"id":"2620840113","title":"Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2620840113","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620840113?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:45","pubTimestamp":1773780300,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., March  17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for peopl","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257702/0/en/Xilio-Therapeutics-to-Present-New-Preclinical-Data-for-its-Masked-T-Cell-Engager-Program-Targeting-CLDN18-2-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4107","LENZ","BK4007","BK4139","BK4117","BK4539","AFG"],"gpt_icon":0}],"pageSize":20,"totalPage":72,"pageCount":2,"totalSize":1433,"code":"91000000","status":"200"}]}}